Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 7/16/20 → 5/10/22 |
Financiación
- AbbVie Incorporated: 25.574,00 US$
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) M16-438
- Hao, Zhonglin (PI)